AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Merger or Acquisition (December 2018)

19 slides from AMAG Pharmaceuticals's merger presentation, Dec 13, 2018

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG’s belief that ciraparantag

  2. Slide 2: Speakers / Agenda

    3 Speakers / Agenda HEMATOLOGY: Ciraparantag Strategic rationale Transaction overview Commercial opportunity Bill Heiden President and Chief Executive Officer Julie Krop, MD Chief Medical Officer Overview of anticoagulation therapies Reversal agents Development strategy and timeline

  3. Slide 3: AMAG's Growing Innovative Pipeline

    4 AMAG's Growing Innovative Pipeline HEMATOLOGY: Ciraparantag * HSDD: Hypoactive Sexual Desire Disorder PHASE 1 PHASE 2 PHASE 3 Regulatory Review Approved/ Marketed Ciraparantag Anticoagulant reversal agent (applying for orphan drug designation) Treatment of iron deficiency anemia AMAG-423 Digoxin I

  4. Slide 4: Ciraparantag: Innovative and Differentiated Product Candidate

    Ciraparantag: Innovative and Differentiated Product Candidate Next-generation anticoagulant reversal agent Small molecule with broad spectrum activity Compelling Phase 2 clinical efficacy and safety data Composition of matter patent through 2034 Investment Thesis High unmet need in a subset of growi

  5. Slide 5: Transaction Overview

    Transaction Overview Acquisition Structured to Mitigate Risk and Maximize Corporate Flexibility HEMATOLOGY: Ciraparantag 1 AMAG was issued a $10 million convertible note from Perosphere as part of an exclusivity arrangement. Proceeds to be offset from up-front consideration at closing. 2 Milestone p

  6. Slide 6: Anticoagulants reduce the ability of the blood to form clots

    Anticoagulants (often referred to as blood thinners) reduce the ability of the blood to form clots Approved to prevent stroke and pulmonary emboli in patients with atrial fibrillation or a history of clots in the legs or lungs ~2% of population of U.S., EU5 and Japan are on a NOAC or LMWH therapy1 ~

  7. Slide 7: NOACs are Quickly Replacing Warfarin

    NOACs are safer and may be more effective than warfarin (over 50% of TRx’s today are for a NOAC) NOACs are Quickly Replacing Warfarin HEMATOLOGY: Ciraparantag 1 AMAG estimated based on IQVIA data. 8 - approved October 2015 - approved October 2010 - approved July 2011 - approved December 2012 - appro

  8. Slide 8: Gaps Exist in Current Anticoagulation Reversal Therapies

    Anticoagulants are associated with a high risk of major and life threatening bleeds in the ER setting Severe bleeds (GI, trauma, intracranial) Need for emergent procedure/surgery NOACs were developed without a reversal agent, which has been a barrier to broader use Anticipate broader future use of N

  9. Slide 9: Well suited for use in emergency room setting

    Well suited for use in emergency room setting Reversal Agent Storage & Preparation Dosing Duration of Action Prothrombotic Signal Praxbind® Biologic that binds Pradaxa® (dabigatran) Requires storage and preparation Needs to be stored at 2o-8o C (36o-46o F) One treatment given as 2 sequential IV dose

  10. Slide 10: Phase 2b Clinical Trial Design

    Placebo-controlled study in age matched cohorts of healthy subjects (50-75 years of age) 16 subjects per dosing cohort; 12 active:4 placebo Subjects received a NOAC (rivaroxaban, apixaban, edoxaban) or LMWH (enoxaparin) until they reached steady state drug levels (3-4 days) Ciraparantag 50, 100, 200

  11. Slide 11: Phase 2 Data Demonstrated Safety and Efficacy

    Ciraparantag demonstrated a statistically significant reduction (p<0.001) in WBCT one hour after dosing for each NOAC and LMWH compared to placebo Phase 2 Data1 Demonstrated Safety and Efficacy, Supporting Phase 3 Development HEMATOLOGY: Ciraparantag 1 Data on file. 13 Eliquis® (apixaban ) - Placebo

  12. Slide 12: Favorable Safety Profile To Date

    Favorable Safety Profile To Date1 HEMATOLOGY: Ciraparantag 1 Data on file. Favorable safety profile in over 250 treated healthy volunteers Most common adverse events were mild sensations of coolness, warmth or tingling, skin flushing, and alterations in taste No serious adverse events No procoagulan

  13. Slide 13: Ciraparantag Phase 3 Clinical Development Program

    Phase 3a clinical trials Study Objective: Establish lowest effective dose after reaching peak steady state blood concentrations of: Xarelto® (rivaroxaban) Eliquis® (apixaban) Savaysa® (edoxaban) Lovenox® (enoxaparin) Study Design: Placebo-controlled dose finding study 60-90 healthy subjects per coho

  14. Slide 14: Ciraparantag Path to Approval

    Ciraparantag Path to Approval HEMATOLOGY: Ciraparantag 1 NDA submission expected to be based on first 50-100 patients in Phase 3b/4 clinical trial, based on precedent. 16 1H-2019 2H-2019 2H-2020 1H-2020 1H-2021 NDA submission1 Potential FDA approval 2H-2021 Close transaction Apply for orphan and bre

  15. Slide 15: AMAG Acquires Perosphere: Adding another novel orphan drug candidate

    Adding another novel orphan drug candidate to pipeline AMAG Acquires Perosphere HEMATOLOGY: Ciraparantag 1 Perosphere sponsored commercial assessment report conducted by a third party in May 2016. 2 Annual U.S. peak revenue opportunity is not guidance, but instead represents what the company believe

  16. Slide 16: Adding another novel orphan drug candidate to pipeline

    Adding another novel orphan drug candidate to pipeline Ciraparantag: The next-generation broad spectrum anticoagulant reversal agent Addresses a serious unmet medical need with significant global commercial potential Aligns with strategy to expand pipeline with innovative development stage compounds

  17. Slide 17: AMAG Acquires Perosphere

    AMAG Acquires Perosphere * Ciraparantag: The next-generation broad spectrum anticoagulant reversal agent * Addresses a serious unmet medical need with significant global commercial potential * Aligns with strategy to expand pipeline with innovative development stage compounds + Broadens AMAG's hemat

  18. Slide 18: AMAG Acquires Perosphere Pharmaceuticals Inc.

    AMAG Acquires Perosphere Pharmaceuticals Inc. December 13, 2018

  19. Slide 19: Slide 19

Amag Pharmaceuticals — Merger or Acquisition (December 2018) on 6ix